Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy

Archives of Neurology

Volumn 58, Issue 9, 2001, Pages 1369-1374

  Valmadrid, Cassandra ^a,d   Voorhees, Carolyn ^a,b,e   Litt, Brian ^c   Schneyer, Christine R ^a,b  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Divine Savior Hospital   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VITAMIN D;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; BONE DISEASE; CALCIUM INTAKE; CHILD; CLINICAL PRACTICE; DIAGNOSTIC TEST; DIET SUPPLEMENTATION; EPILEPSY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

EID: 0034842745     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.9.1369     Document Type: Article

References (61)

1. Osteopathies in antiepileptic long-term therapy
2. Disturbance of calcium metabolism by anticonvulsant drugs
3. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment
4. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status
5. Effect of carbamazepine and valproate on bone mineral density
6. Abnormal skeletal and dental growth in epileptic children
7. Vitamin D-dependent rickets in institutionalized, mentally retarded children receiving long-term anticonvulsant therapy, I: A survey of 288 patients
8. Factors causing rickets in institutionalised handicapped children on anticonvulsant therapy
9. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children
10. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy
11. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure, and diet on vitamin D and calcium metabolism in out-patients with epilepsy
12. Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment
13. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs
14. Bone density and antiepileptic drugs: A case-controlled study
15. Anticonvulsant drugs and bone metabolism
16. Anticonvulsant osteomalacia in epileptic outpatients
17. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults
18. Development of anticonvulsant osteomalacia in epileptic patients on phenytoin treatment
19. Bone disease induced by anticonvulsant therapy and treatment with calcitriol (1,25-dihydroxyvitamin D3)
20. Drug-induced osteomalacia
21. Metabolism and action of vitamin D in epileptic patients on anticonvulsive treatment and healthy adults
22. Abnormal bone metabolism in a neurological setting
23. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting
24. Valproate therapy: Predisposition to bone fracture?
25. Anticonvulsant drugs and bone disease in the elderly
26. Risk factors for hip fracture in white women
27. Risk of age-related fractures in patients with unprovoked seizures
28. Incidence of fracture in epileptics
29. Fracture risk is increased in epilepsy
30. Vitamin D prophylaxis and the lowered incidence of fractures in anticonvulsant rickets and osteomalacia
31. Serum alkaline phosphatase and urinary hydroxyproline values in children receiving phenobarbital with and without vitamin D
32. Bone status in nonambulant, epileptic, institutionalized youth
33. Treatment of anticonvulsant osteomalacia with vitamin D
34. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia
35. Phenobarbital-induced alteration in vitamin D metabolism
36. The effects of anticonvulsant drugs on vitamin D3-activating cytochrome P-450-linked monooxygenase systems
37. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy
38. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro
39. Diphenylhydantoin: Direct inhibition of the vitamin D3-mediated calcium absorptive mechanism in organ-cultured duodenum
40. Principles of Neurology, 6th ed
41. Epilepsy
42. Acquired craniofacial features associated with chronic phenytoin therapy
43. Cancer screening by primary care physicians: A comparison of rates obtained from physician self-report, patient survey, and chart audit
44. Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: A quantitative digital radiography study
45. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years
46. Anticonvulsant drugs and vitamin D metabolism
47. Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children
48. Evaluation of bone mineral density in children receiving antiepileptic drugs
49. An international comparison of vitamin D metabolite measurements
50. International comparison of serum 25-hydroxyvitamin D measurements
51. Redefining vitamin D insufficiency
52. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population
53. Hypovitaminosis D in medical in patients
54. Carbamazepine and bone mineral metabolism
55. Bone matters: Are density increases necessary to reduce fracture risk?
56. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture
57. Incidence of five common fracture types in an institutional epileptic population
58. Incidence and prevalence